Simple blood test could lead to personalized lung cancer treatment

medicalxpress - A single blood test could help doctors predict how lung cancer patients will respond to treatment before therapy begins, researchers have found. University of Queensland-led research focused on non-small cell lung cancer (NSCLC), the most common form of t…

AI Summary: Researchers describe a circulating cell-free methylated DNA liquid biopsy that can detect and track lung cancer by reading tumor-specific methylation patterns in blood. The minimally invasive test aims to guide personalized treatment choices, enable earlier detection of recurrence, and reduce dependence on tissue biopsies—basically doing the diagnostic heavy lifting while you sip your coffee.


Blood tests for monitoring and personalizing lung cancer care

2 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / medicalxpress


MCED trials and clinical benefit debate

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily


Methylation liquid biopsy methods and applications

2 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / nature


All Other Stories

2 months / oncodaily

2 months / medicalxpress

2 months / medicalxpress

2 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily


Back to Top / Wed, May 27, 2026, 12:22 pm / permalink 24379 / 23 stories in 3 months /




Related Stories


National study to use genetic testing to guide cancer survivor follow-up / 3 months

Air pollution causes detectable blood changes years before lung cancer / 15 days

Repeat PSMA PET scans change prostate cancer care for many patients / 6 wks

ctDNA blood test pinpoints who needs chemo after colorectal liver surgery / 7 wks

Early‑onset cancers rising; family history crucial for prevention / 2 months

Ultrasensitive HPV blood test detects head and neck recurrence months earlier / 2 months

Prosigna-guided OPTIMA trial shows chemo can be safely skipped in many ER+/HER2− breast cancers / 2 months

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try FDA, Obesity, Drug Development, None and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.